Kite Pharma to Host Investor Day on October 18, 2016 Spotlighting an Industry-Leading CAR/TCR Pipeline, Next Generation Resea...
October 11 2016 - 8:30AM
Business Wire
Kite Pharma, Inc. (Nasdaq:KITE) today announced that it will
hold an Investor Day on October 18, 2016 in New York where the
company will share updates on its advancing pipeline of chimeric
antigen receptor (CAR) and T cell receptor (TCR) product
candidates, next generation research and development programs, and
KTE-C19 launch readiness. The event and live webcast will begin at
12:00pm Eastern Time. The live audio webcast can be accessed
through the Events and Presentations section under the Investors
tab of Kite’s website at www.kitepharma.com. Following the live
audio webcast, a replay will be available on Kite's website for
approximately 30 days.
About KTE-C19
Kite Pharma’s lead product candidate, KTE-C19, is an
investigational therapy in which a patient's T cells are engineered
to express a CAR to target the antigen CD19, a protein expressed on
the cell surface of B-cell lymphomas and leukemias, and redirect
the T cells to kill cancer cells. KTE-C19 has been granted
Breakthrough Therapy Designation status for diffuse large B-cell
lymphoma (DLBCL), transformed follicular lymphoma (TFL), and
primary mediastinal B-cell lymphoma (PMBCL) by the U.S. Food
and Drug Administration and Priority Medicines (PRIME) regulatory
support for DLBCL in the EU.
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company
engaged in the development of novel cancer immunotherapy products,
with a primary focus on engineered autologous cell therapy (eACT™)
designed to restore the immune system's ability to recognize and
eradicate tumors. Kite is based in Santa Monica, CA. For
more information on Kite Pharma, please
visit www.kitepharma.com. Sign up to follow @KitePharma on
Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The press release may, in some
cases, use terms such as "predicts," "believes," "potential,"
"proposed," "continue," "estimates," "anticipates," "expects,"
"plans," "intends," "may," "could," "might," "will," "should" or
other words that convey uncertainty of future events or outcomes to
identify these forward-looking statements. Forward-looking
statements include statements regarding intentions, beliefs,
projections, outlook, analyses or current expectations concerning,
among other things: the ability to advance the product pipeline,
commercially launch KTE-C19 and research and develop additional
product candidates. Various factors may cause differences between
Kite's expectations and actual results as discussed in greater
detail in Kite's filings with the Securities and Exchange
Commission, including without limitation in its Form 10-Q for the
quarter ended June 30, 2016. Any forward-looking statements that
are made in this press release speak only as of the date of this
press release. Kite assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161011005536/en/
Kite Pharma, Inc.Christine CassianoSVP, Corporate
Communications & Investor
Relationsccassiano@kitepharma.comorGreg MannVP, Investor
Relationsgmann@kitepharma.com
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Apr 2023 to Apr 2024